Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study

Clinical Neuropharmacology · Published 2026-04-17 · DOI 10.1097/wnf.0000000000000686

Authors being retrieved — see the publisher record. https://doi.org/10.1097/wnf.0000000000000686

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Viceroys in the Garden With the Monarch Butterflies: Medical Mimics of Catatonia · Clinical Neuropharmacology · 2025 · Same journal
Impact of Levetiracetam Cost on Epilepsy in a Resource-limited Country · Clinical Neuropharmacology · 2025 · Same journal
Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review · Clinical Neuropharmacology · 2025 · Same journal
Amantadine Reduces Adverse Cardiovascular Outcomes in Patients With Parkinsonism or Parkinson Disease: A Global Propensity Score Matched Analysis · Clinical Neuropharmacology · 2025 · Same journal
A Case of Post–Acute Severe Acute Respiratory Syndrome Coronavirus 2–Induced Focal Nonconvulsive Status Epilepticus With Impairment of Consciousness Initially Diagnosed as Anxiety · Clinical Neuropharmacology · 2025 · Same journal
The Impact of Age and Severity of Attention Deficit Hyperactivity Disorder (ADHD) Before COVID-19 on the Severity of ADHD During the COVID-19 Lockdowns, as Reported by the Mothers · Clinical Neuropharmacology · 2025 · Same journal
Electroconvulsive Therapy for Refractory Anxiety and Depression in Superficial Siderosis: A Case Report · Clinical Neuropharmacology · 2025 · Same journal
A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder · Clinical Neuropharmacology · 2026 · Same journal
Which is More Important to Enhance or Deteriorate Cognitive Functions in Older Adults With Major Cognitive Impairment: The Drug Burden Index or the Total Number of Medications? · Clinical Neuropharmacology · 2025 · Same journal
Sulforaphane Adjunct to Methylphenidate for Attention-deficit/Hyperactivity Disorder: A Randomized, Double-blind, Placebo-controlled Trial · Clinical Neuropharmacology · 2025 · Same journal